Drug Usage Trend study

Anti-rheumatic arthritis drugs

Of the 18 branded drugs in RA treatment, Rheumatrex had the highest usage rate at 69%, followed by Rimatil (56%) and Azulfidine EN (47%). Biologics came in fourth and fifth with Enbrel (32%) and Remicade (30%) respectively. For the rate of product awareness, while the top two products were the same as the usage rates, the level of awareness for Remicade was high, and it came in third. (See graph below) The respondents expected the usage of their main products to increase in the future. The product in which they expect the usage to increase the most was Humira, followed by Actemra.
Also, 30% of the respondents have plans to start using a new product within the next six months.

<Outline>
  • Target samples: n=390 with internal medicine doctors, rheumatology/ connective tissue disease specialists and orthopedic surgeons
  • Study period: May ~ June 2014
  • Studied products: Rheumatrex, Rimatil, Azulfidine EN, Arava, Prograf, Careram, Kolbet, Zeljanz, Enbrel, Remicade, Actemra, Humira, Orencia, Simponi, Cimzia, and other generics
  • Studied items: average monthly number of patients and prescriptions, product awareness and usage rates, product satisfaction, the reasons for use, future usage expectations (short-term), intentions of switching, rate of not switching to generic products, and reasons for adopting new products
  • SSRI Drug Usage Trend study is a physician study that started in 1984, which focuses on products in various therapeutic areas